COR – What goes up, may come down. I think you and some of the other posters on the COR iHub board made much too big a deal of SGP’s willingness to test an ampakine from Organon in ADHD. You guys were practically guaranteeing that SGP was on the verge of doing some kind of deal with COR.
The reality is: SGP has never mentioned the ampakine drug from Organon in any investor presentation. Not even in passing. I wonder if SGP’s inner circle even knows that it exists.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”